Two Part (Double-blind Inclisiran Versus Placebo [Year 1] Followed by Open-label Inclisiran [Year 2]) Randomized Multicenter Study to Evaluate Safety, Tolerability, and Efficacy of Inclisiran in Children (2 to Less Than 12 Years) With Homozygous Familial Hypercholesterolemia and Elevated LDL-cholesterol
Latest Information Update: 26 Nov 2024
Price :
$35 *
At a glance
- Drugs Inclisiran (Primary)
- Indications Hyperlipoproteinaemia type II
- Focus Registrational; Therapeutic Use
- Acronyms ORION-19
- Sponsors Novartis Pharmaceuticals
- 22 Nov 2024 Planned End Date changed from 15 Apr 2029 to 15 May 2029.
- 22 Nov 2024 Planned primary completion date changed from 21 Mar 2028 to 20 Apr 2028.
- 27 Sep 2024 New trial record